AdBio Partners

AdBio Partners, formerly known as Advent France Biotechnology, is a French venture capital firm established in 2016. The firm focuses on early-stage investments in the life sciences sector, particularly in therapeutics-oriented projects. AdBio Partners has made 22 European investments in France, Belgium, Spain, and Ireland, supporting companies in areas such as oncology, inflammation, neurology, infectious diseases, metabolic disorders, rare diseases, enabling technologies, and e-health. The firm's operational team is managed by Alain Huriez and Matthieu Coutet, who bring extensive scientific, medical, and operational expertise to the firm.

AdBio Partners' unique strategy combines early-stage investments in promising enterprises with strong entrepreneurial support to foster company growth. The firm has developed strong relationships within the European innovation ecosystem, attracting international venture capital syndicates to its portfolio companies. This approach has enabled AdBio Partners to establish a significant presence in the European biotech industry.

In September 2021, AdBio Partners closed its second fund, AFB Seed Fund II, with a first close at €86 million ($102 million). This fund aims to create, develop, and finance promising European life sciences start-ups, with the goal of selecting and financing two before the end of 2021. The firm's commitment to supporting innovative biotech ventures underscores its dedication to advancing the European biotech industry.